In this age of targeted therapy, identification of molecular pathways that are deregulated in cancer will not only elucidate underlying tumorigenic mechanisms, but may also help to determine the classes of drugs that are used for treatment. In kidney cancer, a spectrum of histological subtypes exists that are characterized both by distinct molecular signatures and increasingly by distinct molecular pathways that are deregulated in each subtype. For example, the VHL/hypoxia pathway is well-known to be deregulated in clear cell renal cell carcinoma (RCC) whereas in papillary RCC activation of the HGF/Met pathway has been implicated. Additional molecular pathways, many not yet identified, may also be involved in the development of the different histologic subtypes. Moreover, differences in pathway activation may reflect differences in tumor progression and response to treatment. In this article, we describe an oncogenomic approach, based on integrative analysis of gene expression profiling data. In this approach, gene expression data is used to identify both cytogenetic abnormalities and molecular pathways that are deregulated in RCC. Ideally, predicted pathway abnormalities can be linked to predicted cytogenetic abnormalities to identify likely candidate genes. Although further cellular and functional studies are warranted to validate the computational models, development of such models in RCC have the potential to open up new avenues of molecular research and may have significant diagnostic and therapeutic implications.
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Molecular genetics of RCC
Traditionally, one of the most successful methods to identify oncogenic signal transduction pathways that are deregulated in renal cell carcinoma (RCC) has been to perform linkage analysis of rare families that have inherited predispositions for RCC (recently reviewed by Cohen and McGovern, 2005) . Application of this method has successfully identified a number of important kidney cancer oncogenes and tumor suppressor genes that are associated with hereditary kidney cancer syndromes. One of the best known tumor suppressors, the VHL gene, has been identified by positional cloning in families with autosomal dominant von HippelLindau disease characterized by clear cell RCC, cerebellar hemangioblastoma, pheochroocytoma and retinal angioma. What is even more important is that the inactivation of VHL has been demonstrated in the vast majority of sporadic clear cell RCC. In addition, notable for this journal edition, germline activating sequence mutations were identified in the MET receptor tyrosine kinase in hereditary papillary RCC. Other hereditary kidney cancer genes include the gene associated with Birt-Hogg-Dube´syndrome (BHD), fumarate hydrotase (FH), tuberous sclerosis 1 (TSC1) and hyperparathyroidism 2 (HRPT2). However, with the exception of VHL, these genes are rarely mutated in sporadic kidney cancers that are the histological counterparts of their associated hereditary tumors. Furthermore, large-scale screening of DNA sequence mutations in RCC, such as sequence mutations in human protein kinases, have failed to identify frequent mutations in sporadic kidney cancer (data submitted). Therefore, there is a need to identify additional molecular pathways that are deregulated in RCC.
To complement linkage and sequencing-based approaches, a new method to identify signal transduction pathways that are deregulated in sporadic renal cell carcinoma involves the examination of gene expression profiling data to identify gene expression signatures that are reflective of specific oncogene activation or tumor suppressor gene inactivation (Desai et al., 2002; Ferrando et (Bild et al., 2005; Sweet-Cordero et al., 2005) . A variety of computational approaches, including gene set enrichment analysis (GSEA) SweetCordero et al., 2005) , singular value decomposition (Bild et al., 2005) , or parametric statistical tests (Kim and Volsky, 2005) , can be used to determine whether genes that are deregulated by oncogene activation (such as RAS) in tissue culture models are also deregulated in other samples, such as tumor-derived samples. By collecting a series of gene expression signatures that are reflective of different signal transduction events, these signatures can be used as templates to interrogate gene expression data derived from human tumor samples for pathway activation or repression. As such, evaluation of each gene signature using computational approaches can serve as a hypothesis-generating screen to identify signal transduction pathways that are deregulated in RCC.
Molecular pathways in papillary and clear cell RCC
In RCC, initial computational predictions have been successful in the identification of deregulated pathways that reflect the underlying tumor biology. As mentioned previously, the majority of clear cell RCCs are associated with inactivating sequence mutations in one allele of the VHL gene located on 3p25 and loss of the remaining wild-type VHL allele through chromosome 3p deletion. Non-functional VHL activity, as a result of VHL inactivation, leads to inappropriate accumulation of the HIF-1 transcription factor and subsequent induction of a hypoxic cell response. Consistent with this molecular genetic model, sets of genes that are deregulated by VHL loss-of-function in a cell line model are also significantly deregulated in the clear cell RCC tumor samples, but not in the papillary samples ( Figure 1a ). In addition, sets of genes that are deregulated when cells in culture are exposed to hypoxic conditions are also significantly deregulated in the clear cell RCC tumors, but not the papillary tumors. Taken together, these results highlight the specificity that gene expression-based models have in the analysis of RCC. An additional advantage of computational pathway analysis is that in some cases, it may be feasible to quantify partially the strength of the pathway activation or inactivation from the gene expression data. For example, loss of function mutations in the FH gene have been associated with the development of hereditary papillary RCC (Tomlinson et al., 2002) . Although the FH pathway is computationally predicted to be inactivated in both high-grade clear cell and papillary RCC (Figure 1a and b) , closer inspection of the data reveals that the FH pathway is more strongly deregulated in high-grade papillary RCC than the other RCC types (Figure 1c) . In both clear cell and papillary RCC, analysis of gene expression data can identify deregulated pathways that have been implicated in the development of these tumor types. However, computational pathway analysis can also be used to identify novel signalling pathways that are deregulated in renal cancer. For example, we recently identified the MYC pathway as a pathway that is also uniquely activated in a subset of high-grade papillary RCC, but not other high-grade subtypes (Figure 1b) . Encouraging recent work has suggested that analysis of gene expression profiling data has the potential to identify pathways that may be associated with drug sensitivity and drug resistance (Lamb et al., 2006) . These data suggest that it is reasonable to screen gene expression data to identify deregulated pathways in the different RCC subtypes and more generally for the identification of pathways that are deregulated between the different prognostic classes of RCC.
Integration of pathway abnormalities with cytogenetic abnormalities
In addition to pathway prediction, several gene expression profiling studies have demonstrated that changes in DNA copy number result in dramatic changes in gene expression within the abnormal region (Hughes et al., 2000; Phillips et al., 2001; Virtaneva et al., 2001; Xu et al., 2001) . Subsequent studies have shown that it is possible to predict regions of likely DNA copy number changes through examination of the population of mRNA generated from the genes that map to each chromosome (Crawley and Furge, 2002; Harding et al., 2002) . Previously we have shown that we could predict cytogenetic abnormalities with >80% accuracy across the different subtypes of RCC (Furge et al., 2004) . As such, it is possible to correlate specific cytogenetic abnormalities with specific pathway abnormalities through examination of the gene expression data. For example, in high-grade papillary RCC, we were able to correlate activation of the MYC pathway with amplification of chromosome 8q and subsequent overexpression of c-Myc, which maps to chromosome 8q24. Although excellent technologies have recently been developed for high-resolution mapping of DNA copy number changes, our results suggest that a single data set, namely gene expression data, can be fruitfully used to generate three data types: (1) identification of DNA copy number changes, (2) identification of deregulated candidate genes within cytogenetically abnormal regions and (3) linkage of up and downregulation of candidate genes with specific oncogenic signatures reflective of candidate gene activation or inactivation. Advances in all aspects of RCC research are providing insights into tumor development and progression, drug response and patient diagnosis and prognosis. As such, the time resources, financial resources and tissue resources required to carry out cytogenetic studies, gene mutation/protein expression analysis and additional functional studies to identify and validate candidate genes associated with each tumor subgroup is becoming increasingly rate limiting. In an era of limited resources, it will be increasingly important to develop and apply methods such as these to extract as much information as possible from existing data sets. (Furge et al., 2004; Kim and Volsky, 2005) method combined with MYC, E2F3, SRC, RAS, CTNNB1 (b-catenin), synergistic HGF/VEGF VHL, FH, IGF1, wound response, and hypoxia signatures obtained from the literature (Dupont et al., 2001; Gerritsen et al., 2003; Staller et al., 2003; Bild et al., 2005; Adler et al., 2006; Chi et al., 2006; Vanharanta et al., 2006) and the HGF, VEGF, and NF-kB signatures generated using data from the Gene Expression Omnibus (GDS406, GDS495 and GSE2489) were used. Statistics were computed for each up-and downregulated component and then combined. Shown are the percentage of samples that contained active or inactive pathway predictions (Po0.005). (c) The predicted strength of the FH pathway inactivation in low-and high-grade clear cell (CC) and papillary (Pap) RCC. Plotted is the t-statistic derived from parametric analysis of the FH gene signature as described in (a) and (b).
Refinement of methods to identify deregulated pathways in RCC
Although computational predictions of cytogenetic and pathway abnormalities in RCC have the potential to identify novel oncogenic events in RCC, these predictions still require extensive molecular confirmation to test rigorously the computational prediction. Similar to discriminate gene analysis approaches, computational pathway predictions have the potential to generate an unacceptable number of false-positive predictions. In addition, a disadvantage of the computational approach is that whereas it would be ideal to generate gene expression signatures that are reflective of oncogene activation in a model system that most closely resembles the relevant human disease, in practice this rarely happens. For example, it would be ideal to overexpress MYC, RAS, E2F3, etc. in non-transformed human renal-epithelial cells to generate the gene expression signatures that would be used to interrogate renal tumors for pathway activation. However, gene signatures are often derived from a number of experimental models, including a variety of cell line and transgenic animal models, and are generated using a variety of gene expression platforms. One result of these complexities is that gene signatures isolated from the literature have varying degrees of cell-type specific and/or platformspecific components. As noted earlier, activation of the HGF/Met signalling pathway has been associated with the development of hereditary, low-grade, papillary RCC. Using computational approaches, the HGF/Met signalling pathway is not predicted to be active in either high-or low-grade papillary (Figure 1b) . In this case, the HGF gene expression signature was derived from examination of the gene expression changes in MDCK cells (a canine-derived kidney cell line) following HGF stimulation for 24 h. Although it could be that HGF/ MET signalling is not functionally active in sporadic papillary RCC, equally likely it could be that the gene signature isolated from MDCK cells does not have sufficient orthologous gene mappings to accurately transfer a gene signature derived in dog cells to human cells.
Summary
In the near future, advances in the construction of oncogenic gene signatures and advances in bioinformatic approaches to generate more complete genomes and accurate orthologous gene mapping approaches will be of great benefit in the development of computational models of pathway deregulation. Preliminary data are accumulating that the development of these models in RCC will be a fruitful method in identifying pathways that are involved in the development and progression of RCC. Additional work will be needed to both refine the computational models and provide robust molecular and functional studies to test the validity of the computational models.
